1. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxy-methamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 1990;25:521–527.
2. Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine (“Ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151–1156.
3. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–145.
4. Cami J, de la Torre R, Ortuno J, et al. Pharmacokinetics of ecstasy (MDMA) in healthy subjects . Eur J Clin Pharmacol. 1997;52:A168.
5. Verebey K, Alrazi J, Jaffee JH. The complications of ‘Ecstasy’ (MDMA). JAMA. 1988;259:1649–1650.